“…Recently, researchers have demonstrated increased interest in flumazenil, a gammaaminobutyric acid benzodiazepine receptor antagonist. Flumazenil has been indicated primarily for the reversal of the sedative effects of benzodiazepines, often in the case of suspected overdose (Thomson, Donald, & Lewin, 2006). Preliminary data indicate that flumazenil can reduce benzodiazepine withdrawal sequelae (Hood, Norman, Hince, Melichar, & Hulse, 2014).…”